MARKER THERAPEUTICS INC (MRKR) Stock Price, Forecast & Analysis
NASDAQ:MRKR • US57055L2060
MRKR Key Statistics, Chart & Performance
The current stock price of MRKR is 1.63 USD. In the past month the price decreased by -12.83%. In the past year, price increased by 6.54%.
MRKR Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MRKR. When comparing the yearly performance of all stocks, MRKR is one of the better performing stocks in the market, outperforming 77.26% of all stocks.
MRKR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MRKR. MRKR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MRKR Financial Highlights
Over the last trailing twelve months MRKR reported a non-GAAP Earnings per Share(EPS) of -1.19. The EPS decreased by -12.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.78% | ||
| ROE | -77.75% | ||
| Debt/Equity | 0 |
MRKR Forecast & Estimates
9 analysts have analysed MRKR and the average price target is 9.21 USD. This implies a price increase of 464.75% is expected in the next year compared to the current price of 1.63.
For the next year, analysts expect an EPS growth of 19.82% and a revenue growth -62.74% for MRKR
MRKR Ownership
MRKR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.73 | 405.578B | ||
| AMGN | AMGEN INC | 16.99 | 204.31B | ||
| GILD | GILEAD SCIENCES INC | 16.55 | 185.891B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.91 | 122.042B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 83.206B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.69 | 43.51B | ||
| INSM | INSMED INC | N/A | 33.916B | ||
| NTRA | NATERA INC | N/A | 29.129B | ||
| BIIB | BIOGEN INC | 12.83 | 28.815B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.433B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MRKR
Company Profile
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 5 full-time employees. The company went IPO on 2016-11-08. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. The company is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). The company has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Company Info
MARKER THERAPEUTICS INC
2450 Holcombe Blvd, Tmc Partners Office 1.311
Houston TEXAS 77027 US
CEO: Peter Hoang
Employees: 5
Phone: 17134006400
MARKER THERAPEUTICS INC / MRKR FAQ
What does MRKR do?
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 5 full-time employees. The company went IPO on 2016-11-08. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. The company is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). The company has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Can you provide the latest stock price for MARKER THERAPEUTICS INC?
The current stock price of MRKR is 1.63 USD. The price increased by 10.88% in the last trading session.
Does MARKER THERAPEUTICS INC pay dividends?
MRKR does not pay a dividend.
How is the ChartMill rating for MARKER THERAPEUTICS INC?
MRKR has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is MARKER THERAPEUTICS INC (MRKR) stock traded?
MRKR stock is listed on the Nasdaq exchange.
How many employees does MARKER THERAPEUTICS INC have?
MARKER THERAPEUTICS INC (MRKR) currently has 5 employees.
Can you provide the upcoming earnings date for MARKER THERAPEUTICS INC?
MARKER THERAPEUTICS INC (MRKR) will report earnings on 2026-03-30, after the market close.